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ABSTRACT
MiR-145 can regulate cell apoptosis, proliferation,
neural development and stem cell differentiation.
Previous studies indicate that miR-145 is down-
regulated in human colon cancer cells. However,
the molecular mechanisms of miR-145 used to
regulate colon carcinogenesis and angiogenesis
remain to be clarified. Here, we show that the ex-
pression of miR-145 is downregulated in colon and
ovarian cancer tissues and cell lines. MiR-145
inhibits p70S6K1 post-transcriptional expression
by binding to its 30-UTR. The angiogenic factors
hypoxia-inducible factor 1 (HIF-1) and vascular
endothelial growth factor (VEGF), which are down-
stream molecules of p70S6K1, are decreased by
miR-145 overexpression. P70S6K1 rescues miR-
145-suppressed HIF-1 and VEGF levels, tumorigen-
esis and tumor angiogenesis. Furthermore, the
miR-145 level is inversely correlated with the
amount of p70S6K1 protein in colon cancer tissues.
Taken together, these studies suggest that miR-145
serves as a tumor suppressor which downregulates
HIF-1 and VEGF expression by targeting p70S6K1,
leading to the inhibition of tumor growth and angio-
genesis. The miR-145 rescue could be a rationale for
therapeutic applications in colon cancer in the
future.
INTRODUCTION
MicroRNAs are a class of small non-coding RNAs that
have been identiﬁed as a new kind of gene expression
regulators through targeting mRNAs for translational
repression or degradation (1–3). More and more evidence
has shown the important roles of miRNAs in regulating
various cellular functions such as cell apoptosis, cell pro-
liferation, neural development and stem cell differenti-
ation (4–6). Recently, miRNAs are found to play pivotal
roles in tumorigenesis, cancer invasion and metastasis
(7,8). MiR-145 was ﬁrst found to be reduced in colorectal
neoplasia. Then, the deregulation of this miRNA was de-
monstrated in breast, ovarian, lung, nasopharyngeal, blad-
der, gastric and prostate cancers (9–16). The well-known
central tumor suppressor p53 can enhance the post-
transcriptional maturation of several miRNAs, including
miR-145, in response to DNA damage, showing the vital
growth-suppressive function of miR-145 (17). In addition
to its part in cancer development, miR-145 plays an im-
portant role in regulating cell fate and plasticity of smooth
muscle cells (18).
Angiogenesis is a process by which new microvessels
sprout from existing vessels. It is vital for tumorigenesis
and tumor development, because tumors cannot grow
without angiogenesis after their diameters reach 1–2mm
(19). Among all the angiogenic factors, the most potent
one is vascular endothelial growth factor (VEGF), which
is responsible for the growth and permeability of vascular
endothelial cells, vasculature and tumor angiogenesis
(20,21). Hypoxia-inducible factor 1 (HIF-1) is a hetero-
dimeric transcription factor composed of HIF-1a and
HIF-1b subunits, and is a major regulator of VEGF, in
response to hypoxia, by binding to the promoter of VEGF
(22,23). However, there is no information pertaining to
whether or not miR-145 regulates tumor growth and
angiogenesis through mediating the expression of
HIF-1a, and VEGF.
The mammalian target of rapamycin (mTOR)/p70S6K1
is an important signaling pathway in regulating cellular
functions. The activation of p70S6K1 by mTOR
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oligopyrimidine tract, which encodes proteins related with
the translational apparatus like ribosomal proteins, elong-
ation factors eEF1A, eEF2 and the poly A-binding
protein (24). MTOR/p70S6K1 can be activated by the
dysfunction or genetic alterations of its upstream PI3K/
PTEN/AKT signaling pathway or by the overexpression
or ampliﬁcation of p70S6K1 (24,25). Given the important
roles of these proteins in cancerous characteristics such as
the cell cycle, cell apoptosis, cell growth and proliferation,
mTOR/p70S6K1 is proven to be one of the most import-
ant targets in cancer therapy, and its inhibitors exhibit
encouraging effects in animal experiments and clinical
trials (24,26). Evidences by our lab and others demon-
strate that the overexpression of p70S6K1 in both cancer
cells and vascular endothelial cells induces tumor angio-
genesis (27–29). Nevertheless, there is no miRNA that has
been reported to target p70S6K1 up to this point in time.
Colorectal cancers are the third most commonly
diagnosed types of cancer and the third leading cause of
cancer-related death in both men and women (30). In most
studies, miR-145 has been shown to act as a vital tumor
suppressor in colorectal cancers, and its deregulation is
correlated with clinicopathologic features and prognostic
potential in colorectal cancers (12,31,32). On the contrary,
Arndt et al. (33) reported that SW620 stably expressing
miR-145 cells (SW620/miR-145) showed increased cell
proliferation/metabolic activity and its mesenchymal-like
cell morphology, which indicated the oncogenic potential
of miR-145. The demonstrated miR-145 targets include
the Rho-effector rhotekin (RTKN) (34), the metastasis
gene mucin 1 (MUC1) (35), the Ets transcription factor
Friend leukemia virus integration 1 (Fli1) (36), Clathrin
Interactor 1 (CLINT1), core-binding factor b subunit
(CBFB), the protein phosphatase 3 catalytic subunit a
isoform (PPP3CA) (37), the well-known pluripotency fac-
tors OCT4, SOX2 and KLF4 (4), the epidermal growth
factor receptor (EGFR), the nucleoside diphosphate
linked moiety X-type motif 1 (NUDT1) (38), the fascin
homologue 1 (FSCN1) (39), c-Myc (40) and the junctional
adhesion molecule A and fascin (41). A recent study
showed that miR-145 targets the Src family member
YES, which plays a role in cell growth and transform-
ation, and the transcription factor STAT1, which is related
to cell apoptosis and survival, in colon cancer (42).
Moreover, miR-145 is involved in controlling cell apop-
tosis by targeting DNA fragmentation factor-45 (DFF45)
(43), and it inhibits colon cancer cell growth by targeting
oncogene Friend leukemia virus integration 1 gene (FLI1)
(44). However, the role and the underlying mechanisms of
miR-145 in colorectal cancers still remain unclear.
In this study, we demonstrate that: (i) p70S6K1 is the
direct target of miR-145; (ii) the level of miR-145 is
decreased in colon cancers; (iii) miR-145 suppresses
tumor growth and angiogenesis by decreasing HIF-1a
and VEGF expression through targeting p70S6K1
in vitro and in vivo; (iv) the expression of miR-145 is nega-
tively correlated with the p70S6K1 protein levels in colon
cancer tissues. These results demonstrate for the ﬁrst time
that p70S6K1 is a direct target of miR-145 in the regula-
tion of tumor growth and angiogenesis.
MATERIALS AND METHODS
Cell culture, tissue samples and reagents
The human colon cancer cells SW1116 and SW480
(American Type Culture Collection, Manassas, VA,
USA) were cultured in a RPMI 1640 medium that con-
tained a 10% heat-inactivated fetal bovine serum, 100
units/ml, penicillin G and 100mg/ml streptomycin in a
5% CO2 incubator at 37 C. NCM356 cells were purchased
from INCELL (Innovative Life Science Solution, TX,
USA). Cells were maintained in INCELL’s enriched
M3:10 medium, which is M3 medium plus supplements
and 10% fetal bovine serum and antibiotics, and cultured
in 37 C, 5% CO2 humidiﬁed environment. Twenty pairs
of human colon cancer samples, including some primary
colon cancer tissues and paired adjacent normal colon
tissues, were obtained from Huashan Hospital, Shanghai
Medical College, Fudan University, Shanghai, China.
Nine malignant ovarian cancer tissues and nine normal
ovarian tissues were obtained from the Nanjing
Maternal and Child Health Hospital, Nanjing, China. In
all the cases, the diagnoses and grading were conﬁrmed by
two experienced pathologists, which were done in accord-
ance to the principles laid down in the latest World Health
Organization Classiﬁcation. Informed consent was also
obtained from all patients, and the study was approved
by Nanjing Medical University ethics committee. Tissues
specimens that ﬁt into the diagnostic categories of interest
will be identiﬁed by computerized search of the clinical
ﬁles (CoPath) using SNOMED as standardized termin-
ology. Since the analysis will be carried out without access
or notation of any information regulated by HIPAA, this
approach qualiﬁes for the status of NIH Exemption #4.
Protocol for the study has been approved by the Thomas
Jefferson University and Nanjing Medical University
Human Assurances Committees.
P70S6K1, p-p70S6K, PDCD4 and VEGF antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The antibody against HIF-1a and the
growth factor-reduced phenol red-free Matrigel were
o b t a i n e df r o mB DB i o s c i e n c e s(Franklin Lakes, NJ, USA).
The CD31 antibody was from Dako (Carpinteria, CA,
USA). The antibody against b-actin was from Sigma (St
Louis, MO, USA). Moloney murine leukemia virus
(M-MLV) reverse transcriptase, DNA Marker, Taq poly-
merase and oligo(dT)18 were from TaKaRa (Dalian,
China). Lipofectamine 2000 was from Invitrogen
(Carlsbad, CA, USA). A lentivirus-based human
miRNA library was purchased from Open Biosystems
(Huntsville, AL, USA). Anti-miR-145 and the negative
control of miRNA inhibitors were from Ambion
(Applied Biosystems, Carlsbad, CA, USA). TaqMan
qRT-PCR Kit for miR-145, High Capacity RNA-to
cDNA Kit and Power SYBR Green PCR Master Mix
were from Applied Biosystems. The Luciferase (Luc)
assay system was from Promega (San Luis Obispo, CA,
USA). Horseradish peroxidase conjugated anti-mouse and
anti-rabbit antibodies and visualized with enhanced
chemiluminescence reagent, which were from
Perkin-Elmer Life Sciences (Boston, MA, USA).
762 Nucleic Acids Research, 2012,Vol. 40,No. 2Northern blotting
Total RNAs were extracted using Trizol (Invitrogen) ac-
cording to the manufacturer’s instructions. Aliquots of
RNA samples (25mg/sample) were electrophorized on
15% acrylamide and 8M urea denature gels and then
transferred onto Hybond N+ membrane (Amersham
Biosciences, Piscataway, NJ, USA). The membranes were
agitated at 80 C for 2h and then hybridized with oligo-
nucleotide probes corresponding to the complementary
sequences of mature miR-145 and U6. The probes were
labeled at the 5-end using the polynucleotide kinase in the
presence of [g-32P] ATP (GE Healthcare, Piscataway, NJ,
USA). Hybridization was carried out at 39 Ci n
ULTRAhyb
TM-Oligo Hybridization Buffer (Ambion) for
16h. Membranes were washed at 42 C twice with SSC
(2 ) and 0.1% SDS. The membranes were stripped off
by putting them in 1% SDS at 65 C for 30min, and
rehybridized. Images were obtained using the scanner
Storm 860 (Molecular Dynamics, Sunnyvale, CA, USA).
Construction of p70S6K1 30-UTR luciferase plasmids and
reporter assays
A length of 510bp PCR product of p70S6K1 (nt724-1233)
containing its 30-UTR was ampliﬁed by the following
primers: 50-CGGGGATCCGGGTGGACCTGGGGTTT
ATTT-30 (sense) and 50-CCCCTCGAGTTCATCAAAA
GGCCATCAAAT-30 (antisense). The PCR product was
then cloned into a pcDNA6.2 vector. After identifying
the orientation, the correct 30-UTR of p70S6K1 (WT)
was cut from pcDNA6.2 and cloned into pMIR-
REPORTER (ambion, TX, USA). Site-directed mutagen-
esis of the miR-145 seed sequence in p70S6K1-30-UTR
(Mut) was performed by using a Quick change-
mutagenesis kit (Stratagene, CA, USA), with
pcDNA6.2-p70S6K1 WT as the template. The primers
for site-directed mutagenesis were as follows: 50-GCAGT
ACTGCTATGTGCTAAGCTTAACTCCAAGCCTTG
GAATGGG-30 (sense), 50-CCCATTCCAAGGCTTGGA
GTTAAGCTTAGCACATAGTACTGC-30 (antisense).
The mutant p70S6K1-30-UTR was then cloned into
pMIR-REPORTER. For reporter assays, human 293
cells were transiently transfected with WT or Mut
reporter plasmid, pCMV b-galactosidase plasmid, and
miRNA-145 plasmid (Open Biosystems) using lipo-
fectamine 2000. Luciferase (Luc) activity was measured
24h after transfection by using the Luc assay system.
Quantitative real-time PCR
A quantitative real-time RT–PCR was used to determine
the expression levels of miR-145 and VEGF in cells and
tumor tissues. To measure the miR-145 levels, total RNAs
were extracted from cultured cells and tumor tissues using
Trizol (Invitrogen, Carlsbad, CA, USA). The quantitative
real-time RT-PCR analysis of miR-145 levels was per-
formed using the TaqMan Reverse Transcription
Kit and TaqMan MicroRNA Assays Kit (Applied
Biosystems, Carlsbad, CA, USA) according to the manu-
facturers’ instructions. The expression levels of miR-145
were calculated using the delta–delta Ct method with U6
as an internal control.
Real-time PCR was performed to detect the VEGF
mRNA levels using SYBR Green. Reverse transcription
reactions were performed using High Capacity
RNA-to-cDNA Kit according to the manufacturer’s in-
structions. The 100ng of RT product was used for the
PCR reaction using Power SYBR Green PCR Master
Mix. The reaction contained the following: 10mlo f2  
PCR Master Mix, 1ml of forward primer, 1ml of reverse
primer, 1ml of cDNA template, and 7mlo fH 2O. The
reaction program was set at 95 C for 10min, followed
by 40 cycles at 95 C for 15s and 60 C for 30s, and the
melt curve was included. The primers of VEGF are the
forward primer, 50-CGAGGGCCTGGAGTGTG-30 and
the reverse primer, 50-CCGCATAATCTGCATGGTGA
T-30. The primers of GAPDH are the forward primer,
50-ATGGGTGTGAACCATGAGAAGTATG-30 and the
reverse primer, 50-GGTGCAGGAGGCATTGCT-30.
Lentivirus transduction and establishment of stable colon
cancer cell lines expressing miR-145
In order to make miR-145 stably expressed in colon cancer
cells, we used a pLe-miR-145 plasmid from a lentivirus-
based human miRNA library (Open Biosystems, USA),
which can be used in order to overexpress human pre-
miRNA, for packaging the lentivirus and the transduced
colon cancer cell lines SW480 and SW1116. In short,
pLe-miRNA-145 plasmid DNA and the transfection com-
plex DNAs were transfected into 293T cells through the
use of Arrest-In regent according to the company instruc-
tion. The validated, non-silencing, scrambled control was
used as a negative control. Lentiviruses in the supernatant
were collected and used to transduce SW1116 and SW480
cells. Stable cell lines were selected using puromycin.
Adenovirus transduction
Recombinant adenoviruses were made using the AdEasy
system (25). In short, the p70S6K1 cDNA was subcloned
into the vector pAdTrack-CMV and then transferred to
AdEasy-1 plasmid through homologous recombination,
as previously described (26). The viral vectors were then
transfected into Ad-293 cells in order to generate viruses. A
control virus carrying the green ﬂuorescent protein
(Ad-GFP) was derived from the same vector system. The
viruses were titered and 20 multiplicity of infection (MOI)
of Ad-p70S6K1 and Ad-GFP were used to infect cells.
Western blotting
The cells were homogenized in a chilled lysis buffer con-
taining 10mM Tris–HCl (pH 7.4), 1% NP-40, 0.1%
deoxycholic acid, 0.1% SDS, 150mM NaCl, 1mM
EDTA and 1% protease inhibitors. Total proteins were
collected by centrifugation. For tissue samples, tissues
were ground in liquid nitrogen in a radioimmunopre-
cipitation assay buffer, and the total tissue proteins were
extracted as previously described. Twenty micrograms of
lysate proteins were separated by SDS–PAGE and subse-
quently transferred to a nitrocellulose membrane.
Membranes were blocked with 5% non-fat dry milk for
Nucleic AcidsResearch, 2012, Vol.40,No. 2 7632h and incubated with primary antibodies. Protein bands
were detected by incubation with horseradish peroxidase-
conjugated antibodies and visualized with an enhanced
chemiluminescence reagent.
Cell proliferation assay
To determine the effects of miR-145 and its target
p70S6K1 on colon cell proliferation, the parental
SW1116 cells (mock), SW1116 cells stably expressing
pLe-SC and pLe-miR-145 were transduced by Ad-GFP
or Ad-p70 at 20 MOI for 24h and subsequently typsinized
and resuspended. Cells at 1 10
5 were seeded in a 6-well
plate and cultured overnight. The cells were then
trypsinized and counted each day using a hemocytometer
for 7 days of being plated.
In vivo tumor growth assay
The 6-week-old nude mice [BALB/cA-nu (nu/nu)] were
purchased from Shanghai Experimental Animal Center
(Chinese Academy of Sciences, China), maintained in
Figure 1. The expression of miR-145 in colon cancer tissues and cell lines. (A) The expression levels of miR-145 were analyzed in colon cancer tissues
(T) and its adjacent normal tissues (A) by Northern blotting. SnRNA U6 levels were used as an internal control. (B) Tissue samples from normal
ovary and ovarian carcinoma were used to extract total RNAs. The levels of miR-145 were measured by qPCR. U6 was used as an internal control
and the ratio of miR-145/U6 in tumor samples was normalized to that in normal ovary tissues. (C) The expression levels of miR-145 were analyzed by
Northern blotting in normal colon epithelial cell line (NCM356), colon cancer cell lines including CaCo2, SW480, HCT116, CW2, LS174T and SW1116.
The double asterisks indicates signiﬁcant difference when compared to control at P<0.01.
Figure 2. MiR-145 binding resides at p70S6K1 30-UTR region. (A) The
schematic representation of p70S6K1 30-UTR luciferase constructs. The
p70S6K1 30-UTR (nt724-1233) was cloned into pMIR-REPORTER
vector (WT), and the mutant construct was obtained by site-directed
mutagenesis by changing two base pairs of miR-145 seed-sequence
(Mut) and inserted into the vector. (B) 293 cells were transfected
with 0.2mg of WT or Mut reporter, 0.3mg of pLE-miR-145, and
0.1mgo fb-gal plasmids. The relative Luc activity was assayed and
calculated by the ratio of luc/b-gal activity, which was normalized to
that of the control. Results are presented as mean SE from three
duplicates. Double asterisks indicate signiﬁcant difference when
compared to the control (P<0.01).
Table 1. Comparison of nucleotides between the miR-145
seed-sequence and its target in different species
Species p70S6Kl 30-UTR (nt 807-826)
Chimpanzee UGUGCUAAGCUUAACUGGAA
Rhesus UGUGCUAAGCUUAACUGGAA
Mouse UGUGCUAAGCUUAACUGGAA
Rat UGUGCUAAGCUUAACUGGAA
Rabbit UGUGCUAAGCUUAACUGGAA
Shrew UGUGCUAAGCUUAACUGGAA
Hedgehog UGUGCUAAGCUUAACUGGAA
Dog UGUGCUAAGCUUAACUGGAA
Cat UGUGCUAAGCUUAACUGGAA
Horse UGUGCUAAGCUUAACUGGAA
Cow UGUGCUAAGCUUAACUGGAA
Chicken UGUGCUAAGCUUAACUGGAA
Human UGUGCUAAGCUUAACUGGAA
hsa-miR-145 CUAAGGACCCUUUUGACCUG
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diets. All procedures involving animals were approved
by the Institutional Committee on Animal care, Nanjing
Medical University. Twenty mice were randomly divided
into four groups with ﬁve mice per group. Aliquots of
SW1116 cells (1.0 10
6 cells in 50ml) including stable miR-
145-expressing cells and cells infected by Ad-p70S6K1 or
Ad-GFP adenovirus for 24h were mixed with 50ml
growth factor-reduced phenol red-free Matrigel and in-
jected subcutaneously into both ﬂanks of nude mice.
The xenografts were removed from the mice 30 days
after the implantation and trimmed of the surrounding
tissues. Then, the xenografts were weighed. Part of the
tissue samples was snap frozen in liquid nitrogen and
stored at  80 C for analysis.
Semi-quantitative RT-PCR for HIF-1a mRNA levels
Total cellular RNAs were isolated using Trizol reagent
(Invitrogen) according to the manufacturer’s protocol.
RNA at 1mg was used for cDNA synthesis using
oligo(dT)18 and M-MLV reverse transcriptase. The
primers for HIF-1a and GAPDH were as follows: HIF-1a
sense primer: 50-TCGGGCCTCCGAAACCATGA-30;
anti-sense primer: 50-CCTGGTGAGAGATCTGGT
TC-30. GAPDH sense primer: 50-AATGCATCCTGCAC
CACCAACTGC-30; anti-sense primer: 50-GGAGGCCA
TGTAGGCCATGAGGTC-30. HIF-1a and GAPDH
mRNA levels were detected as described previously (45),
and quantiﬁed using UVP VisionworksLS Software.
Immunohistochemical analysis
Tumor samples were ﬁxed with Bouin’s solution (sat-
urated picric acid 300ml, formaldehyde 100ml, glacial
acetic acid 20ml) for 24h, washed with 70% ethanol, and
processed by the parafﬁn-embedded method. The tissues
sections (5mm thick) were then heat-immobilized or
pepsin-immobilized according to the manufacturer’s in-
structions. Antibodies against p70S6K1, HIF-1a, VEGF
and CD31 were used for the immunostaining and detected
through the Dako Envision two-step method of immuno-
histochemistry (Carpinteria, CA, USA). The relative
angiogenesis levels were calculated by microvessel density
(MVD). In short, slides were ﬁrst scanned under low
power ( 40) in order to determine three areas with the
Figure 3. Overexpression of miR-145 decreased p70S6K1 protein expression. SW1116 (A) and SW480 (B) cells stably expressing scrambled control
(SC) and miR-145 were subjected to TaqMan real-time RT-PCR analysis for miR-145 and U6 expression. Results are presented as mean SE from
three duplicate experiments. Double asterisks indicate signiﬁcant difference when compared to the control (P<0.01). (C) The p70S6K1 and
p-p70S6K1 protein levels were analyzed by western blotting in mock cells and cells expressing negative control SC and miR-145 precursor constructs.
(D) Relative densities were quantiﬁed using ImageJ software. Results are presented as mean SE from three duplicates. Asterisk indicates signiﬁcant
difference when compared to the control (P<0.05). (E) Cells were transfected with 25nM of anti-miR-145 inhibitor or negative control inhibitor.
The expression levels of p70S6K1, p-p70S6K1 and b-actin were determined by immunoblotting. Relative density was quantiﬁed using ImageJ
software. Asterisk indicates signiﬁcant difference when compared to the control (P<0.05).
Nucleic AcidsResearch, 2012, Vol.40,No. 2 765maximum number of microvessels that were consequently
evaluated at  200 magniﬁcation. The data are presented
as mean SE from 10 slides for each group.
Statistical analysis
The data represent mean SE except where indicated.
Statistical analysis was performed based on a Student’s
t-test at the signiﬁcance level of P<0.05. Spearman’s
non-parametric correlation test was performed to test
the correlation between the expression levels of miR-145
and p70S6K1 by SPSS.
RESULTS
MiR-145 is downregulated in human colon cancer tissues
To assess whether or not miR-145 is dysregulated in colon
cancer tissues, miR-145 expression levels from colon can-
cer tissues and their adjacent normal tissues are analyzed
by northern blotting. As shown in Figure 1A, the expres-
sion levels of miR-145 in human colon cancer tissues are
much lower than those in the adjacent normal tissues. To
determine whether or not the miR-145 levels were also
downregulated in other types of human cancer, the expres-
sion of the miR-145 level was tested in ovarian carcinoma
tissues and normal tissues by the TaqMan real-time
RT-PCR. When compared to normal ovarian tissues,
the miR-145 level in ovarian carcinoma tissues decreased
to 40%, indicating that the downregulation of miR-145 is
found in both colon and ovarian cancers (Figure 1B).
Further experiments were performed by using normal epi-
thelial cell line (NCM356) and several different colon
cancer cell lines to show that miR-145 expression was un-
detectable or very low in colon cancer cell lines including
CaCo2, SW480, HCT116, CW2, LS174T and SW1116
cells in contrast with normal cells (Figure 1C). These
results indicate that miR-145 is downregulated in both
colon cancer tissues and cancer cell lines.
The p70S6K1 30-UTR is a target of miR-145
To search for the potential targets of miR-145, we found a
putative miR-145 binding site located in the 30-UTR of
Figure 4. Overexpression of miR-145 inhibited VEGF and HIF-1a expression. (A) SW1116 and SW480 cells overexpressing miR-145 were analyzed
for VEGF mRNA levels by TaqMan real-time PCR. Results are presented as mean SE of VEGF mRNA levels from three duplicates. Asterisk
indicates signiﬁcant difference when compared to the control (P<0.05). (B) Mock cells, cells transfected with pLe-SC and pLe-miR-145 were used to
test HIF-1a mRNA levels by semi-quantitative RT-PCR. (C) Total cellular proteins were collected and subjected to western blotting. Forced
expression of miR-145 increased PDCD4 level and inhibited HIF-1a and VEGF protein expression. (D) The protein levels of above study from
three independent experiments are quantiﬁed and presented as mean SE. Asterisk indicates signiﬁcant difference when compared to the control
(P<0.05).
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13 species including human in the region complementary
with the seed sequence (Table 1). To test whether or not
miR-145 targets the 30-UTR region of p70S6K1, p70S6K1
30-UTR containing this seed sequence was cloned into
the pMIR-REPORT miRNA reporter vector (WT). The
forced expression of miR-145 markedly suppressed the
luciferase activity of the wild-type reporter by 50%, sug-
gesting that miR-145 inhibits its 30-UTR function. We also
mutated the miR-145 binding site in the reporter construct
(Mut). Cells were co-transfected with the pLe-miR-145 or
scrambled control plasmid with the wild-type or mutant
Figure 5. Forced expression of p70S6K1 restored VEGF and HIF-1a levels inhibited by miR-145. (A) SW1116 and SW480 cells (mock), and cells
stably expressing SC and miR-145 were infected with adenoviruses carrying GFP (Ad-GFP) or p70S6K1 (Ad-p70) at 20 MOI for 48h. VEGF and
GAPDH mRNA levels were determined by real-time RT-PCR. Lanes 1–4 represent cells expressing Ad-GFP alone, SC +Ad-GFP,
miR-145+Ad-GFP, and cells expressing miR-145+Ad-p70S6K1, respectively. Asterisk indicates signiﬁcant difference when compared to the
control, hash indicates signiﬁcant difference when compared to miR-145+Ad-GFP versus Ad-p70S6K1 groups. (B) The total PDCD4, p70S6K1,
p-p70S6K1, HIF-1a and VEGF protein levels from the above experiment are analyzed by western blotting. Forced expression of p70S6K1 inhibited
PDCD4 expression and restored p70S6K1, HIF-1a and VEGF protein levels in miR-145 stably expressed cells. (C) The signals of PDCD4, p70S6K1,
p-p70S6K1, HIF-1a and VEGF protein levels were obtained and quantiﬁed from three independent experiments. Results are presented as mean SE.
Asterisk indicates signiﬁcant difference when the control vs miR-145 treatment. Hash and double hashes indicate signiﬁcant difference when
compared the miR-145-overexpresing cells treated with or without p70S6K1 overexpression at P<0.05 or at P<0.01, respectively. Groups 1–4:
mock+Ad-GFP, pLe-SC+Ad-GFP, pLe-miR-145+Ad-GFP, pLe-miR-145+Ad-p70S6K1, respectively. (D) Mock cells, cells transduced by
adenoviruses carrying GFP (Ad-GFP) and p70S6K1 dominant negative (Ad-p70S6K1-KD) were used to test expression of PDCD4, HIF-1a and
VEGF by immunoblotting. (E) Quantiﬁcation of signal density by Image J software. Asterisk and double asterisks indicate signiﬁcant difference
when compared to mock or Ad-GFP group at P<0.05 or at P<0.01, respectively.
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(continued)p70S6K1 30-UTR reporter and b-gal plasmids, then the
luciferase activities were assayed. P70S6K1 wild-type but
not mutant reporter activity was affected by the transfec-
tion of pLe-miR-145, suggesting the point mutation of this
seed sequence abolished the effect of miR-145 (Figure 2B).
P70S6K1 protein levels correlate inversely with miR-145
levels in human colon cancer cell lines
Next, to further ensure the validity of these results in
human colon cancer cells, human colon cancer cell lines
SW1116 and SW480 were infected with the lentivirus
carrying miR-145 (pLe-miR-145) or the scrambled control
(pLe-SC) and selected by puromycin. The expression
levels of miR-145 and p70S6K1 were analyzed in these
stable cell lines SW480-miR-145, SW480-SC cells,
SW1116-miR-145 and SW1116-SC using TaqMan
real-time RT-PCR and western blotting. As shown in
Figure 3A and B, the expression levels of miR-145 were
similar in mock cells and miR-SC cells, while increased by
15- and 9-fold in pLe-miR-145-expressing SW1116 and
SW480 cells, respectively (Figure 3A and B), demonstrat-
ing that these stable cells were successfully expressing
miR-145. The cells with miR-145 overexpression showed
low levels of p70S6K1 and p-p70S6K1 proteins by
40–45% decrease compared to the scrambled control
cells (Figure 3C and D). Furthermore, transfection of
anti-miR-145 inhibitor in SW1116 and SW480 cells in-
creased p70S6K1 and p-p70S6K1 expression (Figure 3D
and F). These initial experiments indicate that miR-145
negatively regulated p70S6K1 expression.
VEGF and HIF-1a expression is inhibited by miR-145
Programmed cell death 4 (PDCD4) is a known down-
stream target of p70S6K1 (46,47). We tested the PDCD4
levels in these cells. The results showed an increase in the
levels of PDCD4 in the miR-145-overexpressing cells,
which were consistent with our previous results, suggest-
ing that miR-145 downregulated p70S6K1 for increasing
PDCD4 expression (Figure 4C). VEGF is a crucial
angiogenic factor for controlling vasculature and angio-
genesis. HIF-1a is one of VEGF regulators for inducing
its transcriptional expression by binding to its promoter. It
is well known that p70S6K1 is a key molecule in regula-
tion process of protein synthesis and eukaryotic transla-
tion. Our previous studies have shown that the mTOR/
p70S6K1 signaling pathway mediates tumor angiogenesis
and tumor growth by changing the levels of HIF-1a and
VEGF (45,48,49). Furthermore, to test whether or not the
overexpression of miR-145 in colon cells will have any
effect on VEGF and HIF-1a expression, SW1116-miR-
145, SW1116-SC, SW480-miR-145 and SW480-SC cells
were used to test the levels of VEGF and HIF-1a expres-
sion. As shown in Figure 4A, when compared to the
scrambled control, the VEGF expression in the miR-
145-overexpressing cells was inhibited by about 55 and
40% by TaqMan RT-PCR in SW1116 and SW480 cells,
respectively; while HIF-1a expression did not change at
mRNA level (Figure 4B). Consistent with this result, the
protein levels of VEGF were suppressed by >50% in both
SW1116-miR-145 and SW480-miR-145 cells (Figure 4C
and D). As we anticipated, the protein level of HIF-1a
also showed a similar trend in the miR-145-overexpressing
cells, demonstrating that miR-145 downregulates the ex-
pression of VEGF and HIF-1a (Figure 4C and D).
MiR-145 inhibits VEGF and HIF-1a expression via
p70S6K1
To assess whether or not miR-145 suppressed VEGF and
HIF-1a expression by targeting p70S6K1, we restored
p70S6K1 expression levels in the SW480-miR-145 and
SW1116-miR-145 cells using adenoviruses carrying
p70S6K1 (Ad-p70S6K1). Cells transduced by the
Figure 5. Continued.
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control. The expression levels of PDCD4 were increased
by miR-145 overexpression and attenuated by p70S6K1
overexpression, showing the functional effect of miR-145
(Figure 5B and C). Then, the expression levels of VEGF
were tested by real-time RT-PCR and western blotting,
and p70S6K1, p-p70S6K1 and HIF-1a levels were deter-
mined by western blotting. The overexpression of
p70S6K1 in SW1116-miR-145 and SW480-miR-145 cells
restored the miR-145-inhibited VEGF mRNA level
(Figure 5A). Similarly, the miR-145 overexpression in-
hibited p70S6K1, HIF-1a and VEGF at the protein level
by 40–50%, while the infection with Ad-p70S6K1
markedly recovered the p70S6K1 protein level and re-
stored miR-145-inhibited p70S6K1, p-p70S6K1, HIF-1a
and VEGF expression (Figure 5B and C). In addition,
transduction of adenovirus carrying p70S6K1 dominant
negative mimicked miR-145 overexpression, which showed
increased PDCD4 levels, and decreased HIF-1a and
VEGF expression (Figure 5D and 5E). These results
suggest miR-145 inhibits the expression of HIF-1a and
VEGF by targeting p70S6K1.
MiR-145 inhibits cell proliferation and tumor growth
by downregulating VEGF and HIF-1a expression via
targeting p70S6K1
Next, the cell proliferation assay showed miR-145 over-
expression suppressed cell growth, while forced expression
of p70S6K1 in miR-145-overexpressing cells restored the
cell growth rate (Supplementary Figure S1), suggesting
that miR-145 inhibits cancer cell proliferation through
p70S6K1 expression. Then, we studied the effects of
miR-145 and p70S6K1 on anchorage-independent
growth. As shown in Figure 6A, compared to the mock
(Group1) and scrambled control (pLe-SC, Group 2), the
overexpression of miR-145 decreased the number of colo-
nies to <50% (Group 3), while the presence of p70S6K1 in
miR-145-overexpressing cells restored the number of
colonies to 75% (Group 4). These results indicate that
overexpression of p70S6K1 restores miR-145-inhibited
tumor growth in vitro. Given the important roles of
HIF-1a, and VEGF in inducing angiogenesis and tumor
growth, we tested whether or not miR-145 inhibited tumor
angiogenesis and tumor growth through the reduction of
HIF-1a, and VEGF expression by targeting p70S6K1.
Parental SW1116 cells (mock), SW1116 cells stably ex-
pressing pLe-SC and pLe-miR-145, were transduced by
Ad-GFP or Ad-p70 at 20 MOI for 24h, and the cells
were subsequently typsinized and resuspended. The cells
were mixed with growth factor reduced phenol-free
Matrigel and injected subcutaneously into both ﬂanks of
the nude mice. Xenografts were collected after 30 days of
injection. As shown in Figure 6B, the sizes of xenographs
were similar from mock cells and SW1116-pLe-SC
infected cells, and were much bigger than those from the
SW1116-pLe-miR145 cells. The result indicates that stably
expressed miR-145 in colon cancer cells reduces tumor
growth. When transduced with Ad-p70S6K1, the
SW1116-pLe-miR145 cells formed bigger tumors,
showing that the overexpression of p70S6K1 in miR-145
overexpression cancer cells restored the rate of tumor
growth. Consistent with these results, the overexpression
of miR-145 decreased the tumor weight by 40%, while the
infection of Ad-p70S6K1 caused restoration by 20% when
compared to the miR-145 treated with Ad-GFP group
(Figure 6C).
To further test the expression levels of miR-145 in
tumor tissues from the nude mice, we randomly chose
tumor tissues from each group and analyzed miR-145
level using the TaqMan real-time RT-PCR. The higher
levels of miR-145 expression in the tumors from
SW1116-pLe-miR-145 cells were inversely correlated with
Figure 6. Role of miR-145 in colony formation and tumor growth. (A)
SW1116 mock cells, and cells stably expressing SC and miR-145 were
infected with Ad-GFP or Ad-p70S6K1 at 20 MOI for 24h, then cells
were typsinized, and counted. Cells at 5 10
3 were plated in each well
on 6-well plates with 0.05% soft agar layer. After the incubation of the
cells for 14 days, the number of cell colonies was counted under the
microscope, and the cells were ﬁxed with 100% methanol and stained
with 0.5% crystal violet dye. (B) SW1116 mock cells, and cells stably
expressing SC and miR-145 were infected with Ad-GFP or
Ad-p70S6K1 at 20 MOI for 24h. Cells were implanted into nude
mice. Xenografts were taken out after implantation for 30 days, and
represented tumors are photographed. (C) Tumor weight was obtained
and presented.
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overexpression restored miR-145-inhibiting VEGF expres-
sion level (Figure 7A and B). Similarly overexpression of
miR-145 decreased p70S6K1, HIF-1a and VEGF protein
levels, while the forced expression of p70S6K1 restored
miR-145-inhibited protein expression of p70S6K1,
HIF-1a and VEGF (Figure 7C and D), indicating that
p70S6K1 is upstream regulator of HIF-1a and VEGF.
Immunohistochemistry assays showed that the over-
expression of miR-145 decreased the number of CD-31
positive microvessels to 50%, while the forced expres-
sion of p70S6K1 restored the angiogenesis responses
(Figure 7E). Similar trends were obtained with the expres-
sion levels of HIF-1a, p70S6K1 and VEGF in tumor
tissues, which showed that miR-145 inhibited these protein
levels. The p70S6K1 overexpression increased miR-145-
inhibited HIF-1a, p70S6K1 and VEGF levels (Figure 7F).
Taken together, these results given above, conﬁrmed that
miR-145 decreased HIF-1a and VEGF expression by tar-
geting p70S6K1.
MiR-145 expression is negatively correlated with the
p70S6K1 level in human colon cancer tissues
Twenty pairs of primary colon cancer tissues and adjacent
normal colon tissues were tested for levels of miR-145
expression and U6 mRNA by northern blotting and
for levels of p70S6K1 and b-actin protein expression
by western blotting (Figure 8A and Supplementary
Figure S2). The non-parametric correlation between
miR-145 and p70S6K1 levels was assayed by SPSS
Figure 7. MiR-145 inhibited HIF-1a and VEGF expression through p70S6K1 in vivo. (A and B) Total mRNAs were obtained from tumor tissues of
mock+Ad-GFP, SC+Ad-GFP, miR-145+Ad-GFP, miR-145+Ad-p70S6K1 (Lanes 1–4, respectively). MiR-145 and VEGF mRNA levels were
analyzed by TaqMan real-time RT-PCR using RNAs from 10 different tumors per treatment, and presented as mean SE. Asterisk and double
asterisks indicate signiﬁcant difference when compared control versus miR-145 treatment at P<0.05 and P<0.01, respectively. Hash indicates
signiﬁcant difference when compared miR-145 treatment with versus without p70S6K1 overexpression (P<0.05). (C) The protein levels of p70S6K1,
HIF-1a and VEGF were analyzed in the tumor tissues by western blotting. (D) The signals of p70S6K1, HIF-1a and VEGF protein expression were
obtained from three replicate experiments, and presented as mean SE. Asterisk indicates signiﬁcant difference when the control verus miR-145
treatment (P<0.05). Hash and double hashes indicate signiﬁcant difference when miR-145 treatment with versus without p70S6K1 overexpression at
P<0.05 and P<0.01, respectively. (E) The blood vessels were stained using CD31 antibodies, and positive-stained blood vessels were counted in ﬁve
areas with maximum number of microvessels under the microscope for each slide with 10 slides per experiment. The results are presented as
mean SE (n=10). Asterisk and hash indicate signiﬁcant difference when compared the control versus miR-145, and miR-145 treatment with
versus without p70S6K1 overexpression, respectively (P<0.05). Bar, 100mm. (F) The expression of HIF-1a, p70S6K1 and VEGF were determined in
tumor tissues by immunohistochemistry with representative images showed. Bar, 50mm.
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(continued)software. Spearman’s correlation test showed a signiﬁ-
cant inverse correlation between the miR-145 and
p70S6K1 expression levels exist in colon cancer tissue
with Spearman’s correlation= 0.608, P=0.004, con-
ﬁrming that higher expression levels of miR-145 were sig-
niﬁcantly associated with lower levels of p70S6K1 protein
expression (Figure 8B).
DISCUSSION
Growing lines of studies have demonstrated that miRNAs
are important regulators of protein encoding genes. In
addition to regulating cell reprogramming, neural devel-
opment, cytoskeletal dynamics and smooth muscle cell
fate and plasticity (4,6,18,50,51), miR-145 has been re-
ported to be frequently downregulated in various kinds
of cancers including colon cancer (9,11,12,14,31,32).
Recently, an important discovery indicated that miR-145
was involved in the death-promoting regulatory loop of
p53 (17,52,53), showing the crucial role of miR-145 in
carcinogenesis and cancer development. Our results show
that compared with adjacent normal colon tissues, the
miR-145 levels in colon cancer from clinical samples is
downregulated. These results suggest that miR-145 plays
an important role in colon cancer.
P70S6K1, one of the downstream targets of mTOR,
functions as a key regulator in protein synthesis, thus
controlling various cellular functions such as cell prolifer-
ation, cell cycle and cell apoptosis. The activation and/or
overexpression of p70S6K1 is a hallmark of cancer. This is
the ﬁrst study to show that p70S6K1 is negatively
regulated by miR-145 at the post-transcriptional level by
binding a speciﬁc target site within the 30-UTR (Table 1
and Figure 2). Overexpression of miR-145 in human colon
Figure 7. Continued.
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protein level, further conﬁrming that miR-145 targets
p70S6K1 protein. Some clinical studies have shown that
miR-145 is downregulated in colon cancers (12,31,32,54)
and miR-145 can inhibit tumor growth (31,32). However,
there was opposite conclusion in a different study showing
that miR-145 has oncogenic potential in metastatic colo-
rectal cancer (55). In this study, we showed that higher
levels of miR-145 are closely correlated with lower expres-
sions of p70S6K1 in human colon carcinoma tissues,
indicating that miR-145 may inhibit p70S6K1 expression
in clinical cancer tissues.
HIF-1a and VEGF are important regulators in tumor
angiogenesis, which is required for tumorigenesis and
cancer development (20,56). HIF-1a regulates VEGF at
the transcriptional level by binding to its promoter (23).
Our previous studies demonstrated that p70S6K1 is the
upstream regulator of HIF-1 and VEGF in controlling
tumor growth and angiogenesis in ovarian, lung and
prostate cancers (45,48,49). Consistent with the inhibitory
effect on p70S6K1, the overexpression of miR-145 also
suppresses HIF-1a and VEGF expression in this study.
Furthermore, p70S6K1 overexpression in colon cancer
cells expressing pLe-miR-145 restored miR-145-inhibiting
HIF-1a and VEGF levels, suggesting that miR-145
controls HIF-1a and VEGF expression by targeting
p70S6K1. In vivo studies showed that miR-145 inhibited
colon cancer growth, while forced expression of p70S6K1
restored tumor growth. The expression levels of p70S6K1
in patient colon cancer samples were also reversely related
with miR-145 levels. Consistent with our prediction,
miR-145 expression inhibited angiogenesis by decreasing
p70S6K1, HIF-1a and VEGF levels in tumor tissues,
while p70S6K1 overexpression rescued miR-145-inhibited
p70S6K1, HIF-1a and VEGF expression, and tumor
angiogenesis. Taken together, these in vitro and in vivo
results suggest that miR-145 is a tumor suppressor,
which inhibits tumor growth and angiogenesis through
the inhibition of HIF-1a and VEGF expression by target-
ing p70S6K1.
In summary, our present study suggests that miR-145
negatively regulates p70S6K1 expression at the post-
transcriptional level via a speciﬁc target motif at nt 807–
825 of the p70S6K1-30-UTR, miR-145 suppresses HIF-1a
and VEGF expression by targeting p70S6K1, and inhibits
tumor growth and angiogenesis. We also demonstrate that
levels of miR-145 expression in resected patient colon
tumor tissues are much lower than adjacent normal
tissues, and are inversely correlated with the expression
levels of p70S6K1 protein in the tumors. These results im-
plicate that our results are clinically relevant, and miR-145
overexpression and the inhibitory strategies against
p70S6K1/HIF-1/VEGF signaling pathway may be a ra-
tionale for therapeutic applications in colon cancer in
the future.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Figure 8. The p70S6K1 protein levels were negatively correlated with miR-145 levels in colon cancer tissues. (A) The expression levels of miR-145
were determined by northern blotting and normalized to U6 levels. The fold changes were obtained by the ratio of miR-145 level in cancer tissues (C)
to miR-145 level in adjacent normal tissues. The p70S6K1 protein levels were assayed by immunoblotting and normalized to b-actin. The fold
changes were obtained by the ratio of p70S6K1 to b-actin level. (B) Non-parametric correlation Spearman’s correlation test was used to test the
correlation between the levels of miR-145 and p70S6K1 from 20 pairs of colon cancer and adjacent normal tissues by SPSS software. The protein
levels of p70S6K1 were negatively correlated with miR-145 levels in 20 colon cancer tissues (P<0.05).
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